Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,466 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
p66ShcA functions as a contextual promoter of breast cancer metastasis.
Lewis K, Kiepas A, Hudson J, Senecal J, Ha JR, Voorand E, Annis MG, Sabourin V, Ahn R, La Selva R, Tabariès S, Hsu BE, Siegel MJ, Dankner M, Canedo EC, Lajoie M, Watson IR, Brown CM, Siegel PM, Ursini-Siegel J. Lewis K, et al. Breast Cancer Res. 2020 Jan 15;22(1):7. doi: 10.1186/s13058-020-1245-6. Breast Cancer Res. 2020. PMID: 31941526 Free PMC article.
STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer.
Totten SP, Im YK, Cepeda Cañedo E, Najyb O, Nguyen A, Hébert S, Ahn R, Lewis K, Lebeau B, La Selva R, Sabourin V, Martínez C, Savage P, Kuasne H, Avizonis D, Santos Martínez N, Chabot C, Aguilar-Mahecha A, Goulet ML, Dankner M, Witcher M, Petrecca K, Basik M, Pollak M, Topisirovic I, Lin R, Siegel PM, Kleinman CL, Park M, St-Pierre J, Ursini-Siegel J. Totten SP, et al. Among authors: lewis k. Nat Commun. 2021 Jun 3;12(1):3299. doi: 10.1038/s41467-021-23396-2. Nat Commun. 2021. PMID: 34083537 Free PMC article.
p66ShcA promotes malignant breast cancer phenotypes by alleviating energetic and oxidative stress.
Lewis K, La Selva R, Maldonado E, Annis MG, Najyb O, Cepeda Cañedo E, Totten S, Hébert S, Sabourin V, Mirabelli C, Ciccolini E, Lehuédé C, Choinière L, Russo M, Avizonis D, Park M, St-Pierre J, Kleinman CL, Siegel PM, Ursini-Siegel J. Lewis K, et al. Redox Biol. 2024 Apr;70:103028. doi: 10.1016/j.redox.2024.103028. Epub 2024 Jan 5. Redox Biol. 2024. PMID: 38211442 Free PMC article.
Estimating hepatitis C prevalence in the United States, 2017-2020.
Hall EW, Bradley H, Barker LK, Lewis K, Shealey J, Valverde E, Sullivan P, Gupta N, Hofmeister MG. Hall EW, et al. Among authors: lewis k. Hepatology. 2024 May 13. doi: 10.1097/HEP.0000000000000927. Online ahead of print. Hepatology. 2024. PMID: 38739849
Parenchymal obliteration by renal masses: Functional and oncologic implications.
Kazama A, Munoz-Lopez C, Attawettayanon W, Boumitri M, Maina E, Lone Z, Rathi N, Lewis K, Campbell RA, Palacios DA, Kaouk J, Haber GP, Haywood S, Almassi N, Weight CJ, Remer EM, Ward R, Nowacki AS, Campbell SC. Kazama A, et al. Among authors: lewis k. Urol Oncol. 2024 May 9:S1078-1439(24)00439-3. doi: 10.1016/j.urolonc.2024.04.019. Online ahead of print. Urol Oncol. 2024. PMID: 38729867 Free article.
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.
Menzies AM, Long GV, Kohn A, Tawbi H, Weber J, Flaherty K, McArthur GA, Ascierto PA, Pfluger Y, Lewis K, Tsai KK, Hamid O, Prenen H, Fein L, Wang E, Guenzel C, Zhang F, Kleha JF, di Pietro A, Davies MA. Menzies AM, et al. Among authors: lewis k. Neurooncol Adv. 2024 Mar 18;6(1):vdae033. doi: 10.1093/noajnl/vdae033. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38725995 Free PMC article.
2,466 results